Unfortunately, your browser is too old to work on this website. Please upgrade your browser
9 December 2020

MHRA issues guidance to vaccination centres for managing allergic reactions to the Pfizer/BioNTech COVID-19 vaccine

Summary

A statement by Dr June Raine, Medicines and Healthcare products Regulatory Agency (MHRA) Chief Executive, confirms 'updated guidance' to vaccination centres on managing allergic and anaphylactic reactions following administration of the Pfizer/BioNTech COVID-19 vaccine. She says a group consisting of allergy and clinical immunology experts was convened to review ‘two reports of anaphylaxis and one report of a possible allergic reaction’. Recipients of the vaccine should be ‘monitored for 15 minutes after vaccination, with a longer observation period when indicated’.

Health care professionals administering the vaccine must be trained to recognise anaphylaxis, be familiar with techniques to manage anaphylaxis, and have immediate access to treatment if needed. People with a previous history of anaphylaxis following administration of a vaccine, medicine or food should not receive the Pfizer/BioNTech vaccine. Those who had anaphylaxis following a first dose should not be given a second dose. Health care professionals and members of the public should report side effects using the Yellow Card Scheme.

Source(s)

Gov.uk press release